| Literature DB >> 32318654 |
Rui C Oliveira1,2, Ana Margarida Abrantes1,3, José Guilherme Tralhão1,3,4, Maria Filomena Botelho1,3.
Abstract
Colorectal cancer is a worldwide health burden, with high incidence and mortality, especially in the advanced stages of the disease. Preclinical models are very important and valuable to discover and validate early and specific biomarkers as well as new therapeutic targets. In order to accomplish that, the animal models must replicate the clinical evolution of the disease in all of its phases. In this article, we review the existent mouse models, with their strengths and weaknesses in the replication of human cancer disease progression, with major focus on orthotopic models.Entities:
Keywords: colorectal cancer; mouse model; orthotopic model
Year: 2020 PMID: 32318654 PMCID: PMC7167241 DOI: 10.1002/ame2.12102
Source DB: PubMed Journal: Animal Model Exp Med ISSN: 2576-2095
FIGURE 1A mice exhibiting a subcutaneous heterotopic tumor—in this case, the cells were inoculated at the right side of dorsum
FIGURE 2Colostomy with a nodular and submucosal lesion (black arrow), which on histological examination revealed an adenocarcinoma
Comparison between the different mouse models, with advantages and drawbacks
| Animal model | Advantages | Drawbacks |
|---|---|---|
| Sporadic/chemical induced |
Easy to perform Similar to the carcinogenic process in human |
Low tumor development Wide variability in location, diffusion and differentiation Long time for tumor development |
| Carcinogens in situ |
Similar to the carcinogenic process in human Bypasses enzymatic alterations |
Low tumor development Long time for tumor development |
| Peritoneum models |
Easy to perform Quick results Good for antitumoral drugs tests |
Biological behavior does not mimic/replicate human tumors Biological behavior difficult to predict, usually with disseminated and advanced disease |
| Subcutaneous xenografts |
Use of human cancer cells Quick and easy to use |
Heterotopic inoculation of the tumor is not a physiologic process Low immune system activity Tumoral cancer cells and stromal cells are from different species Nonmetastatic Difficult to predict the response to antitumoral drugs |
| Orthotopic xenografts |
Use of human cancer cells Histology is similar to the human tumors Metastatic potential Replicates the local invasion process by the tumor, with lymphovascular invasion Allows genetic manipulation |
Low immune system activity Tumoral cancer cells and stromal cells are from different species Unable to replicate the initial steps of disease Less tumor formation than subcutaneous xenografts Difficult to predict the response to antitumoral drugs |
| Syngenic |
Tumor cells and stroma are from the same specie Intact immune system |
Endogenic animals does not allow the study of genetic modifiers Low number of metastases |
| Genetic engineered mouse models |
Genetic event is known In situ tumor development Reproduces early stages of oncogenesis Modified gene is expressed on physiologic level Tumor cells and stroma are from the same specie Intact immune system Used for chemoprevention studies |
Only partial replication of the human tumoral morphology and physiology Secondary mutations are different from the human tumors Rarely metastatic Response capacity to antitumoral drugs still unknown |